Humira Biosimilars Gain Traction as Market Dynamics Shift

The pharmaceutical landscape is undergoing a significant transformation as biosimilars to AbbVie's blockbuster drug Humira (adalimumab) gain ground in the market. This shift is reshaping treatment paradigms across multiple specialties and forcing adjustments in prescribing habits.

Biosimilar Uptake Accelerates Amid Pricing Pressures

Immunology physicians are increasingly adopting Humira biosimilars, leading to a notable decline in AbbVie's once-dominant market share. Lynn Price, insights franchise head at Spherix Global Insights, reports that rheumatologists, dermatologists, and gastroenterologists are showing increased acceptance of these alternatives.

The transition has been gradual, with some biosimilar manufacturers facing initial hurdles. Boehringer Ingelheim, for instance, had to lay off staff due to slow uptake of its biosimilar Cyltezo. However, the tide appears to be turning, with doctors now often prescribing 'adalimumab' generically, allowing pharmacies to dispense the formulary-approved version.

Pricing strategies are playing a crucial role in this market shift. Sandoz, through a partnership with CVS subsidiary Cordavis, introduced Hyrimoz at a list price 80% lower than Humira's at the time of launch. This move, coupled with CVS Caremark's decision to remove branded Humira from its formularies in April 2024, has significantly boosted Hyrimoz prescriptions.

Specialty-Specific Trends and New Treatment Paradigms

The impact of biosimilar entry varies across medical specialties, reflecting differences in treatment approaches and available alternatives.

Rheumatology

In rheumatology, Humira's share in advanced rheumatoid arthritis has decreased from 22% to 16% between Q4 2023 and Q4 2024, while biosimilars have grown from 3% to 10%. Hyrimoz has emerged as the preferred biosimilar among rheumatologists, capturing about one-third of adalimumab biosimilar prescriptions.

Dermatology

Dermatologists are not only switching to biosimilars but also moving away from TNF inhibitors like Humira for conditions such as plaque psoriasis. Newer biologics, including Johnson & Johnson's Stelara and Remicade, AbbVie's Skyrizi, and Novartis' Cosentyx, are becoming preferred options. For those still prescribing adalimumab, Amgen's Amjevita leads with a 25% market share among biosimilars.

Gastroenterology

In gastroenterology, Humira use for advanced Crohn's disease has declined from 19% to 14% between Q3 2023 and Q3 2024, while biosimilars have grown from 3% to 6%. The American Gastroenterological Association's revised guidelines for ulcerative colitis now recommend other biologics over adalimumab, potentially influencing prescribing habits for Crohn's disease as well.

As the market continues to evolve, it's clear that Humira's long-standing dominance is giving way to a more diverse treatment landscape. This shift reflects not only the impact of biosimilar competition but also the emergence of new therapeutic options across multiple indications.